Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.85 |
| ▸ | EGFR | P00533 | 3/20 | 0.74 |
| ▸ | TEC | P42680 | 3/20 | 0.74 |
| ▸ | BMX | P51813 | 3/20 | 0.74 |
| ▸ | TXK | P42681 | 2/20 | 0.74 |
| ▸ | LYN | P07948 | 2/20 | 0.74 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.74 |
| ▸ | ITK | Q08881 | 2/20 | 0.74 |
| ▸ | FLT3 | P36888 | 2/20 | 0.74 |
| ▸ | BLK | P51451 | 2/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.74 |
| ▸ | LATS1 | O95835 | 1/20 | 0.74 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.74 |
| ▸ | ABL1 | P00519 | 1/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.74 |
| ▸ | FYN | P06241 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3362233 | 1.00 | BTK (0.85) | BTKEGFRTECBMXTXK | |
| SCHEMBL3362936 | 1.00 | BTK (0.85) | BTKEGFRTECBMXTXK | |
| SCHEMBL3361369 | 0.95 | BTK (0.78) | BTKEGFRFLT3KIT | |
| SCHEMBL3361363 | 0.95 | BTK (0.78) | BTKEGFRFLT3KIT | |
| SCHEMBL1614857 | 0.94 | BTK (0.75) | BTKEGFRTECBMXTXK | |
| SCHEMBL13337309 | 0.93 | BTK (0.84) | BTKEGFRTECBMXTXK | |
| SCHEMBL12713493 | 0.93 | EGFR (0.73) | BTKEGFRTECBMXTXK | |
| SCHEMBL17951804 | 0.92 | BTK (1.00) | BTKEGFRTECBMXTXK | |
| SCHEMBL19813125 | 0.92 | BTK (0.86) | BTKEGFRTECBMXTXK | |
| SCHEMBL19813126 | 0.92 | BTK (0.86) | BTKEGFRTECBMXTXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117064862-A | Ibutenib enteric-coated tablet and preparation method thereof | 山东新时代药业有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-116023397-A | Preparation method of ibrutinib dimer impurity | 深圳振强生物技术有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-115716832-A | Preparation method and application of ibrutinib impurity | 深圳鼎邦化学品有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-10966977-B2 | Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders | TG THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200368235-A1 | IBRUTINIB COMBINATION THERAPY | PHARMACYCLICS LLC (US) | 2020-11-26 | — | — | US | disclosed |
| CN-111317821-A | Ibrutinib combination therapy | 药品循环有限责任公司 | 2020-06-23 | — | — | CN | disclosed |
| US-20190175592-A1 | COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERS | TG THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20160287592-A1 | IBRUTINIB COMBINATION THERAPY | PHARMACYCLICS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160022683-A1 | COMBINATIONS OF BRUTON'S TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS | PHARMACYCLICS, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966977-B2 | Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders | BTK, BCL3, PRKCZ | BTK 1/4885EGFR 1871/4885TEC 287/4885 |
| US-20160287592-A1 | IBRUTINIB COMBINATION THERAPY | BTK, SYK, LYN | BTK 1/4885EGFR 679/4885TEC 30/4885 |
| US-20160022683-A1 | COMBINATIONS OF BRUTON'S TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS | BTK, CYP2E1, CYP3A43 | BTK 1/4885EGFR 1334/4885TEC 97/4885 |
| US-20190175592-A1 | COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERS | BTK, BCL3, PRKCZ | BTK 1/4885EGFR 1871/4885TEC 287/4885 |
| US-20200368235-A1 | IBRUTINIB COMBINATION THERAPY | BTK, SYK, LYN | BTK 1/4885EGFR 679/4885TEC 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.